Ratio of prostate specific antigen to the outer gland volume of prostrate as a predictor for prostate cancer.

Haimin Zhang, Yan Yang, Fang Wang, Wenyu Gu, Guanghui Hu, Junhua ZhengPubMed 2014

TL;DR

This study introduces OPSAD, a novel ratio of prostate-specific antigen (PSA) to the outer prostate gland volume, as a more accurate non-invasive predictor for prostate cancer than PSA or PSA density alone. OPSAD shows promise in reducing unnecessary prostate biopsies and may also serve as a prognostic indicator, correlating with cancer aggressiveness.

What Problem Does This Paper Address?

Prostate cancer is a significant health concern, particularly for aging men. The current gold standard for diagnosis, prostate needle biopsy, is invasive and carries risks of complications like infection and bleeding. Furthermore, elevated PSA levels, a common screening marker, often lead to biopsies in men who do not have cancer, resulting in unnecessary procedures and associated costs and patient anxiety. While existing markers like PSA density (PSAD) and free-to-total PSA ratio aim to improve diagnostic accuracy, their performance remains suboptimal. This paper addresses the need for a more accurate, non-invasive method to differentiate between prostate cancer and benign prostatic hyperplasia (BPH), thereby reducing the burden of unnecessary biopsies.

Methods

The researchers retrospectively analyzed data from 490 patients who underwent ultrasound-guided prostate biopsy due to elevated PSA or suspicious findings on digital rectal examination or ultrasound. They calculated:

  • Prostate Volume (PV): Using the formula 0.52 × superoinferior diameter × transverse diameter × anteroposterior diameter.
  • Inner Gland Volume (IPV): Using the formula 0.52 × superoinferior diameter × transverse diameter × anteroposterior diameter of the inner gland.
  • Outer Gland Volume (OPV): Calculated as PV - IPV.
  • Prostate-Specific Antigen Density (PSAD): PSA / PV.
  • Outer Gland Prostate-Specific Antigen (OPSAD): PSA / OPV.

Statistical analyses, including independent samples t-tests and Receiver Operating Characteristic (ROC) curve analysis, were used to compare the diagnostic performance of PSA, PSAD, and OPSAD.

Datasets

The study utilized a dataset of 490 patients from Shanghai Tenth People's Hospital who underwent prostate biopsy between January 2010 and December 2013. This cohort comprised 133 patients diagnosed with prostate cancer and 357 with benign prostatic hyperplasia (BPH). No new datasets were introduced.

Key Insights and Ideas

  • The Prostate's Anatomy Matters: The study leverages the known anatomical difference between prostate cancer (primarily in the outer gland) and BPH (primarily in the transition zone) to develop a more targeted diagnostic metric.
  • Beyond Total Volume: Simply dividing PSA by the total prostate volume (PSAD) might be insufficient. Focusing on the outer gland volume (OPSAD) appears to be a more refined approach, as it directly relates PSA levels to the region where cancer is most likely to originate.
  • OPSAD as a Superior Discriminator: The results strongly suggest that OPSAD is significantly better at distinguishing prostate cancer from BPH compared to PSA and PSAD. This implies that the ratio of PSA to the specific region where cancer develops is a more potent indicator.
  • Prognostic Potential: The correlation between higher OPSAD values and higher Gleason scores indicates that OPSAD might not only aid in diagnosis but also provide insights into the aggressiveness of the cancer.

Key Results

  • OPSAD is Significantly Higher in Prostate Cancer: Patients with prostate cancer had a mean OPSAD of 1.87 ± 1.26 ng/ml², compared to 0.44 ± 0.21 ng/ml² in patients with BPH (P < 0.05).
  • ROC Curve Superiority: ROC curve analysis revealed that OPSAD had the highest accuracy in predicting prostate cancer, with an area under the curve (AUC) of 0.917, outperforming PSA (AUC = 0.772) and PSAD (AUC = 0.862).
  • High Sensitivity and Specificity: At a cut-off value of 0.69 ng/ml², OPSAD achieved a sensitivity of 94.7% and a specificity of 88.2% for diagnosing prostate cancer.
  • Gleason Score Correlation: OPSAD increased with higher Gleason scores (Gleason 6: 0.92 ± 0.24 ng/ml²; Gleason 7: 2.37 ± 1.90 ng/ml²; Gleason 8: 3.41 ± 0.35 ng/ml²), indicating its potential as a prognostic marker.

Limitations and Future Work

The authors acknowledge that a major limitation of their study is the relatively small sample size. They also note that OPSAD is based on the assumption that tumors predominantly occur in the peripheral zone, which might limit its diagnostic efficacy for cancers originating in the anterior or transition zones.

Future work should focus on:

  • Larger Cohort Studies: Validating these findings in larger, more diverse populations.
  • Normal PSA Levels: Investigating the utility of OPSAD in patients with normal PSA levels (< 4 ng/ml), where current screening methods are less effective.
  • Anterior/Transition Zone Cancers: Further research is needed to understand OPSAD's performance in detecting cancers arising from these less common locations.
  • Prognostic Validation: More extensive studies are required to confirm OPSAD's role as a reliable predictor of prostate cancer prognosis.

Summary updated

Abstract

OPSAD may be used as a new indicator for the diagnosis and prognosis of prostate cancer, and it can reduce the use of unnecessary puncture biopsy of the prostate.
BibTeX
@inproceedings{zhang2014ratio,
  author = {Haimin Zhang and Yan Yang and Fang Wang and Wenyu Gu and Guanghui Hu and Junhua Zheng},
  title = {{Ratio of prostate specific antigen to the outer gland volume of prostrate as a predictor for prostate cancer.}},
  booktitle = {PubMed},
  year = {2014},
}
Figure